Psychotropic and Cognitive-Enhancing Medication Use and Its Documentation in Contemporary Long-term Care Practice

Annals of Pharmacotherapy

Volumn 48, Issue 4, 2014, Pages 438-446

  Rojas Fernandez, Carlos ^a   Mikhail, Mina ^b   Brown, Susan G ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

^b Queenlake Pharmacy   (Canada)

Author keywords

cognitive enhancers; documentation; long term care; psychotropics

Indexed keywords

AMFEBUTAMONE; CENTRAL STIMULANT AGENT; CITALOPRAM; CLONAZEPAM; COGNITIVE ENHANCER; DONEPEZIL; ESCITALOPRAM; GABAPENTIN; GALANTAMINE; HALOPERIDOL; LORAZEPAM; MEMANTINE; MIRTAZAPINE; OLANZAPINE; OXAZEPAM; PAROXETINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SERTRALINE; TRAZODONE; UNCLASSIFIED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; ZOPICLONE; ANTIDEPRESSANT AGENT; HYPNOTIC SEDATIVE AGENT; NEUROLEPTIC AGENT; NOOTROPIC AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DRUG USE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MEDICAL RECORD REVIEW; NURSING HOME PATIENT; PARKINSON DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT DURATION; TREND STUDY; DOCUMENTATION; MIDDLE AGED; NURSING HOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DEMENTIA; DOCUMENTATION; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LONG-TERM CARE; MALE; MIDDLE AGED; NOOTROPIC AGENTS; NURSING HOMES; PSYCHOTROPIC DRUGS;

EID: 84898686789     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028013520196     Document Type: Article

References (47)

1. Kong E,Evans LK,Guevara JP.Nonpharmacological intervention for agitation in dementia: a systematic review and meta-analysis.Aging Ment Health. 2009;13:512-520.
2. Rojas-Fernandez C,Lanctôt KL,Allen D,MacKnight C.Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm?.Pharmacotherapy. 2001;21:74-102.
3. Gauthier S,Cummings J,Ballard C, et al.Management of behavioural problems in Alzheimer's disease.Int Psychogeriatr. 2010;22:346-372.
4. Schneider LS,Dagerman K,Insel PS.Efficacy and adverse effects of atypical antipsychotics for dementia: meta analysis of randomised, placebo controlled trials.Am J Geriatr Psychiatry. 2006;14:191-210.
5. Maher AR,Maglione M,Bagley S, et al.Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.JAMA. 2011;306:1359-1369.
6. Seitz DP,Gill SS,Herrmann N, et al.Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review.Int Psychogeriatr. 2013;25:185-203.
7. Huybrechts KF,Rothman KJ,Silliman RA,Brookhart A,Schneeweiss SF.Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes.CMAJ. 2011;183:E411-E419.
8. Selbaek G,Kirkevold O,Engedal K.The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes.Int J Geriatr Psychiatry. 2007;22:843-849.
9. Kamble P,Chen H,Sherer JT,Aparasu RR.Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of national survey data.Drugs Aging. 2009;26:483-492.
10. Testad I,Auer S,Mittleman M, et al.Nursing home structure and association with agitation and use of psychotropic drugs in nursing home residents in three countries: Norway, Austria, and England.Int J Geriatr Psychiatry. 2010;25:725-731.
11. Nishtala PS,McLachlan AJ,Bell JS,Chen TF.Determinants of antipsychotic medication use among older people living in aged care homes in Australia.Int J Geriatr Psychiatry. 2010;25:449-457.
12. Wetzels RB,Zuidema SU,de Johnghe JFM,Verhey FRJ,Kooopmans RTCM.Prescribing pattern of psychotropic drugs in nursing home residents with dementia.Int Psychogeriatr. 2011;23:1249-1259.
13. Bronskill SE,Anderson GM,Sykora K, et al.Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact.J Am Geriatr Soc. 2004;52:749-755.
14. Puyat JH,Law MR,Wong ST,Sutherland JM,Morgan SG.The essential and potentially inappropriate use of antipsychotics across income groups: an analysis of linked administrative data.Can J Psychiatry. 2012;57:488-495.
15. Parsons C,Briesacher BA,Givens JL,Chen Y,Tjia J.Cholinesterase inhibitor and memantine use in newly admitted nursing home residents with dementia.J Am Geriatr Soc. 2011;7:1253-1259.
16. Herrmann N,Gill SS,Bell CM, et al.A population based study of cholinesterase inhibitor use for dementia.J Am Geriatr Soc. 2007;55:1517-1523.
17. Dybicz SB,Keohane DJ,Erwin WG,McRae T,Shah SN.Patterns of cholinesterase inhibitor use in the nursing home setting: a retrospective analysis.Am J Geriatr Pharmacother. 2006;4:154-160.
18. Mansour D,Wong R,Kuskowski M,Dysken M.Discontinuation of acetylcholinesterase inhibitor treatment in the nursing home.Am J Geriatr Pharmacother. 2011;9:345-350.
19. Daiello LA,Ott BR,Lapane KL, et al.Effect of discontinuing cholinesterase inhibitor therapy on behavioural and psychological symptoms in nursing home patients with dementia.Am J Geriatr Soc. 2009;7:74-83.
20. McCleery J,Fox R.Antipsychotic prescribing in nursing homes.BMJ. 2012;344:e1093.
21. Gauthier S,Patterson C,Chertkow H, et al.Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD4).Can Geriatr J. 2012;15:120-126.
22. Tjia J,Gurwitz JH,Briesacher BA.Challenge of changing nursing home prescribing culture.Am J Geriatr Pharmacother. 2012;10:37-46.
23. Herrmann N,Gauthier S.Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease.CMAJ. 2012;179:1279-1287.
24. Ballard C,Hanney ML,Theodoulou M, et al.The dementia antipsychotic withdrawal trial (DART-AD): long term follow up of a randomized placebo-controlled trial.Lancet Neurol. 2009;8:151-157.
25. Nishtala PS,McLachlan AJ,Bell JS,Chen TF.A retrospective study of drug related problems in Australian aged care homes: medication reviews involving pharmacists and general practitioners.J Eval Clin Pract. 2011;17:97-103.
26. Morris JN,Fries BE,Mehr DR, et al.MDS cognitive performance scale.J Gerontol. 1994;49:M174-M182.
27. Powel Lawton M,Casten R,Parmelee PA,Van Haitsma K,Corn J,Kleban MH.Psychometric characteristics of the minimum dataset II: validity.J Am Geriatr Soc. 1998;46:736-744.
28. Declerq T,Petrovic M,Azermai M, et al.Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.Cochrane Database Syst Rev. 2013; (3): CD007726.
29. Rosenblatt A,Samus QM,Onyike CU, et al.Acetylcholinesterase inhibitors in assisted living: Patterns of use and association with retention.Int J Geriatr Psychiatry. 2008;23:178-184.
30. Lyketsos CG,Samus QM,Baker A, et al.Effect of dementia and treatment of dementia on time to discharge from assisted living facilities: The Maryland assisted living study.J Am Geriatr Soc. 2007;55:1031-1037.
31. Kroger E,van Marum R,Souverein P,Egberts T.Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands. A retrospective cohort study.Drugs Aging. 2010;27:663-675.
32. Pariente A,Pinet M,Moride Y, et al.Factors associated with persistence of cholinesterase inhibitor treatments in the elderly.Pharmacoepidemiol Drug Saf. 2010;19:680-686.
33. Amuah JE,Hogan DB,Eliasziw M, et al.Persistence with cholinesterase inhibitor therapy in a population based cohort of patients with Alzheimer's disease.Pharmacoepidemiol Drug Saf. 2010;19:670-679.
34. Hogan DB,Bailey P,Black S, et al.Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia.CMAJ. 2008;179:1019-1026.
35. Mitka M.CMS seeks to reduce antipsychotic use in nursing home residents with dementia.JAMA. 2012;308:119-121.
36. Briesacher BA,Tjia J,Field T,Peterson D,Gurwitz JH.Antipsychotic use among nursing home residents.JAMA. 2013;309:440-442.
37. Ballard C,Margallo-Lana M,Juszczak E, et al.Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomized double blind placebo controlled trial.BMJ. 2005;330:874.
38. Vigen CLP,Mack WJ,Keefe RSE, et al.Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.Am J Psychiatry. 2011;168:831-839.
39. Street JS,Clark S,Gannon KS, et al.Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double blind, randomized, placebo controlled trial.Arch Gen Psychiatry. 2000;57:968-976.
40. Martin HM,Slyk MP,Deymann S,Cornacchione MJ.Safety profile assessment of risperidone and olanzapine in long-term care patients with dementia.J Am Med Dir Assoc. 2003;4:183-188.
41. Mulsant BH,Gharabawi GM,Bossie CA, et al.Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine.J Clin Psychiatry. 2004;65:1708-1714.
42. Bergh S,Selbaek G,Engedal K.Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomized, parallel group, placebo controlled trial.BMJ. 2012;344:e1566.
43. Rojas-Fernandez C,Mikhail M.Contemporary concepts in the pharmacotherapy of depression in older people.Can Pharm J (Ott). 2012;145:128-135.
44. Pollock BG,Mulsant BH,Rosen J, et al.Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis an behavioral disturbances in hospitalized, demented patients.Am J Psychiatry. 2002;159:460-465.
45. Briesacher BA,Limcangco R,Simoni-Wastila L,Doshi J,Gurwitz J.Evaluation of nationally mandated drug use reviews to improve patient safety in nursing homes: a natural experiment.J Am Geriatr Soc. 2005;53:991-996.
46. Forsetlund L,Eike MC,Gjerberg E,Vist GE.Effect of interventions to reduce potentially inappropriate use of drugs in nursing homes: a systematic review of randomised controlled trials.BMC Geriatr. 2011;11:16.
47. Lam JM,Anderson GM,Austin PC,Bronskill SE.Family physicians providing regular care to residents in Ontario long-term care facilities.Can Fam Physician. 2012;58:1241-1248.